Eric Lefebvre - 19 Dec 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: Chief Medical Officer
Signature: /s/ Mike Ouimette, attorney-in-fact
Issuer symbol: PLRX
Transactions as of: 19 Dec 2022
Transactions value $: -$207,968
Form type: 4
Filing time: 21 Dec 2022, 20:32:36 UTC
Previous filing: 27 Oct 2022
Next filing: 25 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Award	$0	+21.9K	+16.39%	$0.00	155K	19 Dec 2022	Direct	F1
transaction	PLRX	Common Stock	Sale	-$208K	-10.9K	-7.01%	$19.10	144K	20 Dec 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,876 shares.
F2	The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4.

Content

On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,876 shares.

The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4.